| 1. |
- Luo, Xiyu, et al.
(author)
-
Effects of local compositional heterogeneity in mixed halide perovskites on blue electroluminescence
- 2024
-
In: Matter. - 2590-2393. ; 7:3, s. 1054-1070
-
Journal article (peer-reviewed)abstract
- Compositional heterogeneity is commonly observed in mixed bromide/iodide perovskite photoabsorbers, typically with minimal effects on charge carrier recombination and photovoltaic performance. Consistently, it has so far received very limited attention in bromide/chloride-mixed perovskites, which hold particular significance for blue light-emitting diodes. Here, we uncover that even a minor degree of localized halide heterogeneity leads to severe non-radiative losses in mixed bromide/chloride blue perovskite emitters, presenting a stark contrast to general observations in photovoltaics. We not only provide a visualization of the heterogeneity landscape spanning from micro-to sub-microscale but also identify that this issue mainly arises from the initially formed chloride-rich clusters during perovskite nucleation. Our work sheds light on a long-term neglected factor impeding the advancement of blue light-emitting diodes using mixed halide perovskites and provides a practical strategy to mitigate this issue.
|
|
| 2. |
- Wu, Xuanjun, et al.
(author)
-
Protective Epitope Discovery and the Design of MUC1 Based Vaccine for Effective Tumor Protections in Immunotolerant Mice
- 2018
-
In: Journal of the American Chemical Society. - : American Chemical Society (ACS). - 0002-7863 .- 1520-5126. ; 140:48, s. 16596-16609
-
Journal article (peer-reviewed)abstract
- Human mucin-1 (MUC1) is a highly attractive antigen for the development of anticancer vaccines. However, in human clinical trials of multiple MUC1 based vaccines, despite the generation of anti-MUC1 antibodies, the antibodies often failed to exhibit much binding to tumor presumably due to the challenges in inducing protective immune responses in the immunotolerant environment. To design effective MUC1 based vaccines functioning in immunotolerant hosts, vaccine constructs were first synthesized by covalently linking the powerful bacteriophage Qβ carrier with MUC1 glycopeptides containing 20-22 amino acid residues covering one full length of the tandem repeat region of MUC1. However, IgG antibodies elicited by these first generation constructs in tolerant human MUC1 transgenic (Tg) mice did not bind tumor cells strongly. To overcome this, a peptide array has been synthesized. By profiling binding selectivities of antibodies, the long MUC1 glycopeptide was found to contain immunodominant but nonprotective epitopes. Critical insights were obtained into the identity of the key protective epitope. Redesign of the vaccine focusing on the protective epitope led to a new Qβ-MUC1 construct, which was capable of inducing higher levels of anti-MUC1 IgG antibodies in MUC1.Tg mice to react strongly with and kill a wide range of tumor cells compared to the construct containing the gold standard protein carrier, i.e., keyhole limpet hemocyanin. Vaccination with this new Qβ-MUC1 conjugate led to significant protection of MUC1.Tg mice in both metastatic and solid tumor models. The antibodies exhibited remarkable selectivities toward human breast cancer tissues, suggesting its high translational potential.
|
|
| 3. |
- Yin, Zhaojun, et al.
(author)
-
Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice
- 2018
-
In: ACS Chemical Biology. - : American Chemical Society. - 1554-8929 .- 1554-8937. ; 13:6, s. 1668-1676
-
Journal article (peer-reviewed)abstract
- Mucin-1 (MUC1) is one of the top ranked tumor associated antigens. In order to generate effective anti-MUC1 immune responses as potential anticancer vaccines, MUC1 peptides and glycopeptides have been covalently conjugated to bacteriophage Qβ. Immunization of mice with these constructs led to highly potent antibody responses with IgG titers over one million, which are among the highest anti-MUC1 IgG titers reported to date. Furthermore, the high IgG antibody levels persisted for more than six months. The constructs also elicited MUC1 specific cytotoxic T cells, which can selectively kill MUC1 positive tumor cells. The unique abilities of Qβ-MUC1 conjugates to powerfully induce both antibody and cytotoxic T cell immunity targeting tumor cells bode well for future translation of the constructs as anticancer vaccines.
|
|
